Gyrolab® Blog Biopharma Issues Insights and Assay Development

Maximizing immunoassay performance in modern biopharma

Advantages of small-volume analytical technologies in gene therapy

Advantages of Automated Immunoassays

Automated detection of dsRNA contaminants in mRNA samples

Gyrolab automated platform – faster delivery of immunoassay data and more information per data point

Choosing the Right Automated Immunoassay Platform for Your Analytical Needs

Automated hybridization assays to measure ASO drug levels in biological samples

Generic assays for ADA assessment in rodents

Host Cell Protein (HCP) Impurities in Biotherapeutic Drug Development and Manufacturing

New Gyros Protein Technologies Kit Boxes Launch

Pre-existing anti-AAV immunity: a hidden barrier to gene therapy

Enhancing AAV gene therapy: Insights from Bayer’s immunogenicity testing study

Overcoming Challenges in Electrochemiluminescence Assays (ECLA) During Pre-Clinical PK Studies with Microfluidic Technology

How to Address ELISA Challenges in Preclinical PK Studies with Advanced Microfluidic Technology

Advancing PK Studies: The Role of Microsampling in Monoclonal Antibody Therapeutics

Anti-interferon autoantibodies play a major role in the age-related severity of COVID-19

Matching microsampling with miniaturized bioanalysis is revolutionizing pharma biotherapeutic development

Accurate ligand affinity determination: in-solution Adnectin KD measurement

Accurate ligand affinity determination: high-affinity ligands for use in cancer immunotherapy

Boost COVID-19 vaccine R&D with rapid serology tests and minimal sample and reagent consumption (Part III)

Immunoassays to measure SARS-CoV-2 antibodies in serum (Part II)

Serology tests in COVID-19 research and vaccine development (Part I)

Capsid titer quantification for AAV-based therapeutics

A new spin on ultra-high biomolecular affinity determination

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part I

Boosting vaccine development and production in a post-pandemic era with fast, high-performance immunoassays: Part II

How to think about HCP impurity testing

Enhancing the productivity of immunoassays: a 2-plex Gyrolab assay for both preclinical and clinical studies

How to be confident in immunoassay determination of free versus bound target or drug

Improving quality and speed in immunoassay development, validation, and routine use

Weighing up the advantages and disadvantages of multiplex assays

Solutions to immunoassay interference, cross reactivity and other challenges

Putting a new spin on immunoassays for cell and gene therapy – Part 2

Putting a new spin on immunoassays for gene therapy – Part 1

Next generation antibody therapeutics move into prokaryotes

Ligand binding assays for regulated bioanalysis

How to get it right the first time

ADME of therapeutic proteins